Skip to main content

Aurinia Pharm Ord(AUPH-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low15.63
Day High15.91
Open:15.91
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Aurinia Pharmaceuticals to Acquire Kezar, Expanding Autoimmune Pipeline
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: MoonLake Immunotherapeutics (MLTX), Neumora Therapeutics, Inc. (NMRA) and Aurinia Pharmaceuticals (AUPH)
Tipranks
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Aurinia Pharmaceuticals (AUPH)
Tipranks
Aurinia to Buy Kezar Life Sciences in Cash-and-CVR Autoimmune Deal
Business Wire
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
Tipranks
Aurinia Reshapes C-Suite as Investor Kevin Tang Takes CEO Role Without Pay
Tipranks
Aurinia Reshapes Executive Team as Board Chair Kevin Tang Becomes CEO
Business Wire
Aurinia Announces Management Transition
Tipranks
Analysts Offer Insights on Healthcare Companies: Aurinia Pharmaceuticals (AUPH), MAIA Biotechnology, Inc. (MAIA) and CG Oncology, Inc. (CGON)
Tipranks
Analysts Conflicted on These Healthcare Names: Collegium Pharmaceutical (COLL), MannKind (MNKD) and Aurinia Pharmaceuticals (AUPH)
Tipranks
Analysts Are Bullish on These Healthcare Stocks: Rhythm Pharmaceuticals (RYTM), Teleflex (TFX)
Tipranks
Aurinia Lifts Profits on LUPKYNIS Growth and Sets Double-Digit 2026 Revenue Outlook
Tipranks
Aurinia Lifts Revenue on LUPKYNIS Growth, Sets Strong 2026 Sales Outlook
Business Wire
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress
Tipranks
Aurinia Sets February 26 Date to Report 2025 Results and Business Update
Business Wire
Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026
Motley Fool
Rare-Disease Biotech PTC Is Surging — And One Fund Just Raised Its Bet. Should You?
Motley Fool
Celcuity Stock Near All-Time Highs — And This Major Biotech Investor Is Still Jumping In
Motley Fool
Precigen Stock Up 280% in a Year — Is FDA Approval Behind This Big New Investor Bet?
Motley Fool
Aurinia Raises Guidance and Shares Are Surging— Is This Why a Major Investor Just Boosted Its Stake?
Tipranks
Bloom Burton downgrades Aurinia Pharmaceuticals (AUPH) to a Hold
Tipranks
H.C. Wainwright Keeps Their Buy Rating on Aurinia Pharmaceuticals (AUPH)
Tipranks
Aurinia Pharmaceuticals Reports Strong Q3 2025 Earnings
Tipranks
Aurinia Pharma’s Earnings Call Highlights Growth and Challenges
Tipranks
Aurinia Pharmaceuticals (AUPH) was downgraded to a Hold Rating at RBC Capital
Tipranks
Aurinia Pharmaceuticals Boosts 2025 Sales Guidance Amid Strong Q3 Performance
Tipranks
Aurinia Pharmaceuticals Reports Strong Q3 2025 Growth and Raises Sales Guidance
The Globe and Mail
Wednesday’s analyst upgrades and downgrades
Shopify Inc. headquarters signage in Ottawa on Tuesday, May 3, 2022.
Tipranks
Aurinia Pharmaceuticals to Announce Q3 2025 Financial Results and Business Update
Business Wire
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress
Business Wire
Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025
Tipranks
Aurinia Pharmaceuticals Advances Lupus Nephritis Study in Young Patients

Profile

Aurinia Pharmaceuticals Inc. is a late stage biopharmaceutical company. It focuses on the development of therapeutic immunomodulating drug candidate. The company's lead drug includes Voclosporin for the treatment of lupus nephritis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.